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Abstract
Background: The detection of copy number variants (CNVs) and the results of CNV-disease association studies rely on how
CNVs are defined, and because array-based technologies can only infer CNVs, CNV-calling algorithms can produce vastly
different findings. Several authors have noted the large-scale variability between CNV-detection methods, as well as the
substantial false positive and false negative rates associated with those methods. In this study, we use variations of four
common algorithms for CNV detection (PennCNV, QuantiSNP, HMMSeg, and cnvPartition) and two definitions of overlap
(any overlap and an overlap of at least 40% of the smaller CNV) to illustrate the effects of varying algorithms and definitions
of overlap on CNV discovery.
Methodology and Principal Findings: We used a 56 K Illumina genotyping array enriched for CNV regions to generate
hybridization intensities and allele frequencies for 48 Caucasian schizophrenia cases and 48 age-, ethnicity-, and gender-
matched control subjects. No algorithm found a difference in CNV burden between the two groups. However, the total
number of CNVs called ranged from 102 to 3,765 across algorithms. The mean CNV size ranged from 46 kb to 787 kb, and
the average number of CNVs per subject ranged from 1 to 39. The number of novel CNVs not previously reported in normal
subjects ranged from 0 to 212.
Conclusions and Significance: Motivated by the availability of multiple publicly available genome-wide SNP arrays,
investigators are conducting numerous analyses to identify putative additional CNVs in complex genetic disorders.
However, the number of CNVs identified in array-based studies, and whether these CNVs are novel or valid, will depend on
the algorithm(s) used. Thus, given the variety of methods used, there will be many false positives and false negatives. Both
guidelines for the identification of CNVs inferred from high-density arrays and the establishment of a gold standard for
validation of CNVs are needed.
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Introduction
Rapidly developing technologies such as chip array-based
genotyping platforms have facilitated recent large-scale interroga-
tion of the human genome. Many of these investigations have been
successful in identifying specific single nucleotide polymorphisms
(SNPs) associated with complex disorders [1,2], but these
investigations cannot identify all forms of genetic variation because
they focus on the common SNPs [1]. The availability of densely
spaced SNPs generated by genome-wide studies has also enabled
the investigation of genome structural variations, such as copy
number variants (CNVs). CNVs range in size from a few to several
thousand base pairs (bp), and because they frequently affect gene
dosage or structure, they are likely to have a biological impact.
Furthermore, CNVs are likely enriched in genes encoding proteins
related to human evolution and environmental adaptation [3],
making CNVs ideal candidates for genetic susceptibility factors in
complex disorders such as schizophrenia.
The presence of CNVs is inferred through array-based
technologies using calling algorithms that can vary substantially
and that can result in vastly different findings. These inferences are
made based on hybridization intensities and allele frequencies.
Large ratios of normalized intensities and/or higher than
anticipated heterozygosity at specific genomic locations indicate
excessive hybridization and suggest that a duplication, triplication,
or other excess copies of the genomic region may exist, whereas
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14456small intensity ratios or long runs of homozygosity suggest that a
deletion may be present.
The detection of previously undiscovered CNVs and the results
of CNV-disease association studies rely on how CNVs are defined.
Several authors have noted the large-scale variability between
CNV-detection methods, as well as the substantial false positive
and false negative rates associated with those methods (e.g.,
Winchester et al. [4], Zhang et al. [5]). For example, Winchester
et al. [4] examined the results of a number of different SNP-based
algorithms, including Birdsuite [6], Chromosome Copy Number
Analysis Tool (CNAT) (www.Affymetrix.com), Genome Alteration
Detection Algorithm (GADA; [7]), PennCNV [8], and Quan-
tiSNP [9]. These algorithms were applied to CEPH sample
NA12156 from HapMap, which was genotyped using both
Illumina and Affymetrix arrays, as well as sequenced for structural
variations using fosmid end-pair sequence (EPS) methods [10].
Whereas the EPS method detected a total of 638 CNV events, the
number of events reported by the CNV algorithms ranged from 8
to 546, and the false positive rate (based on lack of overlap with the
molecular method) ranged from 51% to 80%. Using the 299
events detected by Kidd et al. [10] on another CEPH sample
(NA15510), Winchester et al. [4] found false negative rates ranging
from 77% to 96%. Additionally, they compared consistency across
algorithms and found that no pair of algorithms had greater than
60% concordance. Consequently, Winchester et al. [4] recom-
mend using multiple algorithms and using software specific to the
array platform that generated the data to identify CNVs.
Whether a CNV is newly discovered compared to the CNVs
cataloged in a reference database depends on how overlap with
previously discovered CNVs is defined. There are at least two
issues to consider: (1) how to combine ‘‘overlapping’’ CNVs found
in unique individuals into one CNV and (2) how to determine
whether a potential newly discovered CNV overlaps with a
reference CNV. Redon et al. [11] define CNV regions (CNVRs) as
the union of locations where CNVs from multiple individuals have
any (i.e., at least 1 bp) overlap, and Perry et al. [12] use this
definition, as do Cooper et al. [13]. Redon et al. [11] also define
independent juxtaposed CNVs according to the criterion that
individual-specific CNVs must overlap by more than a threshold
proportion (e.g., 40% of the length of each CNV) in order to be
merged. In the context of identifying de novo CNVs in an individual
that were not present in either parent, McCarroll et al. [14] use
stringent criteria, joining CNVs across samples only if they overlap
across at least 80% of their length. Wain et al.’s [15] definition of
CNV loci is similar to Redon et al.’s independent juxtaposed
CNVs except that the CNV locus is defined as the intersection (not
the union) of the overlapping CNVs. Wain et al. [15] showed that
the selection of overlap threshold for defining CNV loci affected
the nominal significance level in a genome-wide association study
of amyotrophic lateral sclerosis. However, the general effects of
overlap definitions on identified CNVs have not been specifically
compared across studies.
In this study, we use variations of four common algorithms for
CNV detection (PennCNV [8], QuantiSNP [9], HMMSeg [16],
and cnvPartition [17]) and two definitions of overlap (any overlap
and an overlap of at least 40% of the smaller CNV; see Figure 1) to
illustrate the effects of varying algorithms and definitions of
overlap on CNV identification and discovery. Our initial sample
included 50 Caucasian schizophrenia cases and 48 age-, ethnicity-,
and gender-matched control subjects who were evaluated with a
56 K Illumina genotyping array enriched for CNV regions
(deCODE; www.decode.com). Although no algorithm variation
found a difference in CNV burden between the two groups (results
not shown), we found substantial differences between the results
generated by the algorithms for the number of CNVs, size of
CNVs, CNVs per person, and whether or not we discovered novel
CNVs.
Results
Merging CNVs Reported in Published Databases
As of March 2009, there were 29,292 CNVs reported in the
literature from normal subjects [18,19,20,21,22,23]. However, after
merging CNVs across individuals and between studies, only 6,735
unique CNVs (i.e., CNVRs) exist when applying the ‘‘any’’ overlap
criteria (Table 1). Of the 3,581 CNVs reported in the literature for
schizophrenia subjects [20,21,22,23], only 479 were not already
reported for normal subjects, and of these, 418 are unique. Using
the ‘‘40% either’’ overlap criterion instead of the ‘‘any’’ overlap
criterion increases these numbers only slightly (Table 1). Supple-
mental Figures S1, S2, S3, S4 show summary statistics for the
numbers and sizes of CNVs within merged CNV groups.
Effect of Algorithms on Number of CNVs Detected
Table 2 shows the number of CNVs detected in 96 subjects (48
schizophreniasubjects and 48control subjects)for eachalgorithm by
type (loss versus gain; see Methods). The total number of CNVs
detected ranged from 3,765 based on PennCNV alone to 102 based
on requiring HMMSeg, cnvPartition with a 3-probe minimum,
PennCNV, and QuantiSNP to all identify the same CNV. With the
exception of the algorithms that involved cnvPartition with a 10-
probe minimum, most of the detected CNVs were less than 100
kilobases (kb). For all the detected CNVs, losses were more common
than gains, with the ratio ranging from 7-to-1 to 2-to-1. Again, with
the exception of the algorithms that involved cnvPartition with a 10-
probe minimum, most of the losses were less than 100 kb, whereas
for all of the algorithms except PennCNV, most of the gains were
greater than or equal to 100 kb. The average size of the detected
CNVs ranged from 46 kb based on PennCNV alone to 787 kb
based on cnvPartition with a 10-probe minimum (Table 3). The
largest CNV found by PennCNV or HMMSeg alone was under 2
megabases (Mb), and the largest found by QuantiSNP alone was
slightly under 5 Mb, but all other algorithms (all of which involved
cnvPartition) detected a 10-Mb CNV. The average number of
CNVs per person (Table 4) ranged from 39.2 based on PennCNV
alone to 1.1 based on requiring two algorithms (HMMSeg and
cnvPartition with a 10-probe minimum) or four algorithms
(HMMSeg, cnvPartition with a 3-probe minimum, PennCNV,
and QuantiSNP) to all identify the same CNV. Note that for six of
the algorithms, there were several subjects with no CNVs detected.
For Tables 2, 3, and 4, the results of algorithms that involve
determining overlap (the last four rows listed in each table) were the
sameregardlessofwhichdefinitionofoverlapwasused(‘‘any’’versus
‘‘40% either’’; see the Methods section and Figure 1). Supplemental
Figure S5 shows the range of sizes of overlapping CNVs (within
individualand chromosome)bychromosomeforCNVsidentifiedby
requiring HMMSeg, cnvPartition with a 3-probe minimum,
PennCNV, and QuantiSNP to all identify the CNV.
Effect of Algorithms on Number of ‘‘Newly Discovered’’
CNVs
Figure 2, supplemental Figures S6, S7, S8, S9, S10, and Tables 5
and 6 demonstrate that we found widely varying results depending
on the algorithm(s) used. Figure 2 demonstrates that requiring
both cnvPartition with a 3-probe minimum and HMMSeg to
identify CNVs using the ‘‘any’’ overlap criterion results in finding
one CNV not previously reported in the literature for normal
subjects (a gain at genomic locations 25046920–25130278 on
Effect of Algorithms on CNVs
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subject, thus no novel CNVs were discovered in schizophrenia
subjects. Using HMMSeg alone with the ‘‘any’’ overlap criterion,
we found two novel CNVs (both gains) in schizophrenia subjects
(supplemental Figure S6), whereas using only cnvPartition with a
3-probe minimum with the ‘‘any’’ overlap criterion, we found
three novel CNVs (all losses) in schizophrenia subjects (supple-
mental Figure S7). Thus, using either algorithm alone resulted in
discovering novel CNVs in schizophrenia subjects (although not of
the same type), but using the criterion that both algorithms must
identify the same CNV resulted in the discovery of no novel CNVs
in schizophrenia subjects.
Tables 5 and 6 show results for all ten algorithms. Using the
‘‘any’’ overlap criterion, the number of novel CNVs compared to
previously published normal databases ranged from 189 to 0 over
the ten algorithms, and the number of novel CNVs found in our
Table 1. Number of CNVs in Normal and SCZ databases based on the literature, by overlap algorithm.
Overlap Algorithm1 Merged CNVs in Normals
2
CNVs in SCZ from Lit, Not Previously
Discovered in Normals
3
Merged Version of CNVs in SCZ from Lit,
Not Previously Discovered in Normals
Loss Gain Both Total Loss Gain Both Total Loss Gain Both Total
Any 4,007 1,273 1,455 6,735 135 344 479 119 293 6 418
40% Either 4,293 1,426 1,506 7,225 167 414 581 148 357 6 511
1‘‘Any’’ overlap means the CNVs share at least one base pair. ‘‘40% either’’ overlap means that the length of the overlap has to be at least 40% of the size of at least one
of the CNVs.
2Normals database contains 29,292 CNVs (9,538 gains; 18,983 losses; 771 both) before any kind of internal merging based on overlap is performed.
3SCZ database contains 3,581 CNVs before omitting any CNVs that overlap with the CNVs in Normals database.
doi:10.1371/journal.pone.0014456.t001
Figure 1. Illustration of how CNVs are merged based on the ‘‘any’’ overlap criterion (A) and the ‘‘40% either’’ overlap criterion (B).
(A) CNVs that have any overlap are merged. The start position of the resulting CNV is defined to be the minimum base pair position of the
overlapping CNVs, and the end position is defined to be the maximum base pair position of the overlapping CNVs. (B) CNVs are merged only if the
length of overlap is at least 40% of the size of at least one of the CNVs. The start position of the resulting CNV is defined to be the minimum base pair
position of the overlapping CNVs, and the end position is defined to be the maximum base pair position of the overlapping CNVs.
doi:10.1371/journal.pone.0014456.g001
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normal or schizophrenia subjects ranged from 55 to 0 (Table 5).
Using the ‘‘40% either’’ overlap criterion resulted in a slightly
higher number of novel CNVs (Table 6). The coordinates of
CNVs not previously published in databases of normal subjects are
given in supplemental Datasets S1–S10 in File S1.
Discussion
Multiple recent studies have used new whole-genome genotyp-
ing methods to discover structural variations in the DNA segments
of normal subjects and subjects with a variety of disorders. The
identification of novel rare CNVs in autism (NRXN1, SHANK3,
and CNTNAP2 [24]) and schizophrenia [21] has generated much
excitement. These CNVs range in size from a kb to several Mb.
The majority of these CNVs are thought to be rare, highly
penetrant, and found in only a small number of individuals (e.g.,
,1% of subjects with schizophrenia). However, the role of specific
genes within these CNVs that are associated with schizophrenia
remains unknown.
We, Zhang et al. [5], and others [4] demonstrate that the
number of CNVs identified depends on the algorithm(s) utilized.
Because CNVs are inferred from observed intensity data instead of
being directly called, as is the case for SNP genotypes, Winchester
Table 2. Number of CNVs detected in 96 subjects by each algorithm.
All CNVs CNVs ,100 kb CNVs $100 kb
Algorithm Loss Gain Total Loss Gain Total Loss Gain Total
PennCNV
1 2,531 1,234 3,765 2,280 966 3,246 251 268 519
HMMSeg
2 664 302 966 584 27 611 80 275 355
cnvPartition with 3 Probes
3 590 103 693 432 28 460 158 75 233
cnvPartition with 5 Probes
3 427 87 514 289 12 301 138 75 213
cnvPartition with 10 Probes
3 175 75 250 93 4 97 82 71 153
QuantiSNP
4 159 81 240 117 21 138 42 60 102
HMMSeg & cnvPartition with 3 Probes
5 262 37 299 215 2 217 47 35 82
HMMSeg & cnvPartition with 5 Probes
5 172 37 209 129 2 131 43 35 78
HMMSeg & cnvPartition with 10 Probes
5 71 34 105 35 1 36 36 33 69
HMMSeg & cnvPartition with 3 Probes & PennCNV &
QuantiSNP
6
87 15 102 56 2 58 31 13 44
1Default settings, then CNVs ,10 bp omitted.
2HMMSeg using Cooper et al. [13] implementation.
3Default settings, except minimum number of probes required to identify that a CNV was varied.
4Default settings, then CNVs with Log Bayes Factor ,30 omitted.
5Only CNVs identified by both HMMSeg and cnvPartition that overlap are included.
6Only CNVs identified by HMMSeg, cnvPartition, PennCNV, and QuantiSNP that overlap are included.
doi:10.1371/journal.pone.0014456.t002
Table 3. Size of CNVs (kb) detected in 96 subjects by each algorithm.
All CNVs CNVs ,100 kb CNVs $100 kb
Algorithm Mean SD Min Max Mean SD Min Max Mean SD Min Max
PennCNV 46 105 0.003 1,623 17 25 0.003 100 226 195 100 1,623
HMMSeg 126 215 1 1,751 16 25 1 100 316 260 100 1,751
cnvPartition with 3 Probes 345 998 0.1 10,283 31 33 0.1 99 966 1,544 102 10,283
cnvPartition with 5 Probes 443 1,138 1 10,283 40 35 1 99 1,013 1,605 102 10,283
cnvPartition with 10 Probes 787 1,550 8 10,283 30 17 8 94 1,266 1,827 103 10,283
QuantiSNP 410 849 1 4,733 39 36 1 99 911 1,123 100 4,733
HMMSeg & cnvPartition
with 3 Probes
247 801 1 10,283 28 32 1 99 827 1,375 103 10,283
HMMSeg & cnvPartition
with 5 Probes
344 942 2 10,283 38 36 2 99 857 1,403 103 10,283
HMMSeg & cnvPartition
with 10 Probes
607 1,270 8 10,283 32 10 8 52 907 1,484 121 10,283
HMMSeg & cnvPartition
with 3 Probes & PennCNV
& QuantiSNP
345 1,129 2 10,283 45 43 2 99 740 1,646 110 10,283
See Table 2 for explanation of algorithms.
doi:10.1371/journal.pone.0014456.t003
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one. However, although the net effect of this strategy decreases the
false positive rate, it also increases the false negative rate.
Furthermore, Carter [25] notes that it is inevitable that any
hybridization studies will generate false positive and false negative
results, regardless of how the data are analyzed. It is particularly
important that these two rates are assessed in any study that uses
SNP arrays for CNV detection, as high false positive rates will lead
to publicly available databases becoming populated with regions
incorrectly called as CNVs. However, without a true gold standard
(e.g., full-genome sequencing), the false positive and false negative
rates of any particular algorithm or combination of algorithms are
impossible to estimate. Many of the regions in CNV databases
today will prove to be false discoveries, particularly loci that have
not been validated independently or are not replicated between
studies [25]. Finally, in hybridization studies, standardized
measures of uncertainty (e.g., confidence intervals) are unavailable
in the literature due to unknown statistical properties of the
algorithms (e.g., some published results were derived from
algorithms that include manual inspection), inconsistent definitions
of a ‘‘reference’’ genome, and a lack of commonly implemented
gold standards.
Despite multiple reports of associations between specific CNVs
and a disease, it is important to note that CNVs are also
commonly found in normal individuals [26], and the presence of a
CNV does not necessarily indicate that it is related to the disease
phenotype [27]. Therefore, the selection of the appropriate
reference database of CNVs found in ‘‘normal’’ individuals is
critical. With a few exceptions, the majority of previous
publications do not discuss in detail the definition of ‘‘novel’’
CNVs, that is, CNVs that were not previously found in normal
reference databases or literature. We demonstrate that the choice
of algorithm and overlap criteria affects how many (if any) CNVs
are found that have not been previously reported in the literature.
Limitations of this study include the relatively low array density
of the 56 K chip we used compared to current commonly used
higher density chips. However, both Winchester et al. [4], who
used Illumina 1 M and Affymetrix 6.0 arrays, and Zhang et al. [5],
who used the Affymetrix 6.0 array, also found large variability in
the number of CNVs detected depending on the algorithm used.
Another limitation of our study is that because we did not find
novel CNVs associated with schizophrenia, we did not proceed
with molecular validation. However, the main point of this study
was to demonstrate the marked variability in putative CNV
detection between algorithms, not to demonstrate whether any of
the CNVs were in fact valid.
In summary, both better guidelines for identifying CNVs using
high-density arrays and a gold standard for validation of CNVs are
needed. Although the availability of high-density SNP arrays
increases the opportunity for discovery of novel genetic variants,
much caution is necessary to establish CNV–disease associations.
In general, molecular validation is necessary to confirm the
presence of CNVs. Ultimately, the role of putative ‘‘disease-
causing’’ gene(s) that are disrupted within CNVs will require
additional confirmatory molecular genetic and molecular biologic
studies. The application of the various algorithms to datasets that
do not include molecular validations will generate many false
positives. Issues of sensitivity and specificity will need to be further
evaluated with next-generation sequencing (such as genomic
resequencing data from the 1000 Genome Project; http://
browser.1000genomes.org/index.html). The availability of ge-
nome-wide sequencing data will help to establish consensus
guidelines for the identification and validation of true CNVs.
Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. Both the Consortium on the
Table 4. Number of CNVs per person detected in 96 subjects by each algorithm.
All CNVs CNVs ,100 kb CNVs $100 kb
Algorithm Mean SD Min Max Mean SD Min Max Mean SD Min Max
PennCNV 39.2 11.2 14 78 33.8 9.0 14 60 5.4 4.8 0 30
HMMSeg 10.1 3.4 3 26 6.4 1.9 3 12 3.7 2.7 0 17
cnvPartition-with 3 Probes 7.2 3.6 1 23 4.8 2.3 1 12 2.4 2.7 0 20
cnvPartition with 5 Probes 5.4 3.1 1 23 3.1 1.7 0 7 2.2 2.6 0 20
cnvPartition with 10 Probes 2.6 2.6 0
a 21 1.0 0.9 0 3 1.6 2.3 0 19
QuantiSNP 2.5 2.7 0
b 20 1.4 1.2 0 5 1.1 2.5 0 19
HMMSeg & cnvPartition-with 3
Probes
3.1 1.7 0
c 8 2.3 1.4 0 7 0.9 1.1 0 5
HMMSeg & cnvPartition with 5
Probes
2.2 1.5 0
d 6 1.4 1.1 0 5 0.8 1.1 0 5
HMMSeg & cnvPartition with 10
Probes
1.1 1.2 0
e 5 0.4 0.5 0 2 0.7 1.0 0 5
HMMSeg & cnvPartition with 3
Probes & PennCNV & QuantiSNP
1.1 1.1 0
f 5 0.6 0.8 0 3 0.5 0.8 0 4
See Table 2 for explanation of algorithms.
a4 control and 5 schizophrenia subjects with no identified CNVs.
b6 control and 6 schizophrenia subjects with no identified CNVs.
c1 control and 2 schizophrenia subjects with no identified CNVs.
d5 control and 5 schizophrenia subjects with no identified CNVs.
e15 control and 19 schizophrenia subjects with no identified CNVs.
f19 control and 17 schizophrenia subjects with no identified CNVs.
doi:10.1371/journal.pone.0014456.t004
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Washington (UW) Alzheimer’s Disease Research Center (ADRC)
studies were approved by both the UW institutional review board
and the VA Puget Sound Health Care System institutional review
board. All subjects provided written informed consent for the
collection of samples and subsequent analyses.
Subjects
We recruited 50 schizophrenia subjects and 20 control subjects
between 2003 and 2008 as part of the NIH-funded COGS [28].
Schizophrenia subjects met the DSM-IV-TR criteria for schizo-
phrenia via the administration of the Diagnostic Interview for
Genetic Studies (DIGS; [29]) and the Family Interview for Genetic
Figure 2. Process Flow Chart based on overlap between HMMSeg and cnvPartition (3-probe minimum). Numbers are based on the
‘‘any’’ overlap criterion. All data on sex chromosomes have been omitted. Gains are compared only to gains or both, and losses are compared only to
losses or both.
doi:10.1371/journal.pone.0014456.g002
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and inclusion/exclusion criteria are discussed in detail by Calkins
et al. [28]. Control subjects did not meet DSM criteria for
schizophrenia or other psychotic disorders and did not have a
family history of schizophrenia or other psychotic disorders. An
additional 28 control subjects were obtained from the UW ADRC
[31].
Of the 50 schizophrenia subjects, DNA from 1 subject was not
genotyped due to poor DNA quality, and 1 subject was omitted
from the analysis due to a substantially lower call rate compared to
all of the other samples. The 48 remaining schizophrenia subjects
had a mean age of forty-one years (SD 12), and 9 (19%) were
female, compared with a mean age of forty-four years (SD 13) for
the 48 control subjects, of whom 9 (19%) were female.
SNP Genotyping
Weprepared DNAfromperipheralbloodsamplesusingstandard
protocols in order to avoid artifacts related to transformation and
cell culture. We submitted 98 samples (50 schizophrenia subjects
and 48 age-, ethnicity-, and gender-matched controls) to deCODE
Genetics (www.decode.com) for genotyping. Because of our specific
interest in CNVs, we chose to genotype our samples using the 56 K
CNV-enriched deCODE-Illumina BeadChip array. This platform
contains 52,167 markers: 34,965 polymorphic markers (67%) and
17,202 nonpolymorphic markers (33%). After excludingmarkers on
sex chromosomes, there were 46,875 markers, including 32,159
polymorphic markers (69%) and 14,716 nonpolymorphic markers
(31%), with an average distance of 59 kb between markers (SD =
228 kb, range =1 to 21,470 kb).
Table 5. ‘‘Newly discovered’’ CNVs detected by each algorithm based on 48 normal and 48 schizophrenia subjects, using the
‘‘any’’ overlap criterion.
Algorithm
CNVs Not Previously Discovered
in Normals
CNVs Found Only in SCZ, Not
Previously Discovered in
Normals
CNVs Found Only in SCZ, Not
Previously Discovered in Normals
or SCZ
Loss Gain Both Total Loss Gain Both Total Loss Gain Both Total
PennCNV 72 84 33 189 24 31 2 57 24 29 2 55
HMMSeg 4 6 10 2 2 2 2
cnvPartition with 3 Probes 12 2 14 3 3 3 3
cnvPartition with 5 Probes 10 1 11 4 4 4 4
cnvPartition with 10 Probes 2 2 1 1 1 1
QuantiSNP 1 1 0 0
HMMSeg & cnvPartition with 3 Probes 1 1 0 0
HMMSeg & cnvPartition with 5 Probes 1 1 0 0
HMMSeg & cnvPartition with 10 Probes 0 0 0
HMMSeg & cnvPartition with 3 Probes &
PennCNV & QuantiSNP
10 0
See Table 2 for explanation of algorithms.
doi:10.1371/journal.pone.0014456.t005
Table 6. ‘‘Newly discovered’’ CNVs detected by each algorithm based on 48 normal and 48 schizophrenia subjects, using the ‘‘40%
either’’ overlap criterion.
Algorithm
CNVs Not Previously Discovered
in Normals
CNVs Found Only in SCZ, Not
Previously Discovered in
Normals
CNVs Found Only in SCZ, Not
Previously Discovered in Normals
or SCZ
Loss Gain Both Total Loss Gain Both Total Loss Gain Both Total
PennCNV 83 98 31 212 30 34 2 66 30 28 2 60
HMMSeg 6 10 16 1 4 5 1 3 4
cnvPartition with 3 Probes 14 4 18 3 3 3 3
cnvPartition with 5 Probes 10 3 13 4 4 4 4
cnvPartition with 10 Probes 2 1 3 1 1 1 1
QuantiSNP 1 1 0 0
HMMSeg & cnvPartition with 3 Probes 1 2 3 1 1 0
HMMSeg & cnvPartition with 5 Probes 2 2 0 0
HMMSeg & cnvPartition with 10 Probes 1 1 0 0
HMMSeg & cnvPartition with 3 Probes &
PennCNV & QuantiSNP
11 0 0
See Table 2 for explanation of algorithms.
doi:10.1371/journal.pone.0014456.t006
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We received SNP intensity data on genotypes with a call rate of
greater than 95% from deCODE and then read these into
Illumina’s BeadStudio software (version 3.1.3.0; Genotyping
version 3.3.7; Illumina Genome Viewer 3.2.9; www.illumina.
com). Intensities were normalized by forming clusters using the
raw data (as opposed to forming clusters using some external
source, such as HapMap samples). The resulting log2 R ratios
(LRR) and B-allele frequencies (BAF) [32] were used to identify
CNVs on autosomes for each subject. We used variations of four
algorithms for CNV detection: PennCNV [8] (May 1, 2010),
QuantiSNP [9] (version 2.3), Cooper et al.’s [13] implementation
of the Hidden Markov Segmentation Model (HMMSeg, [16]), and
cnvPartition [17] (version 1.2.1). For PennCNV, we used the
default settings, then omitted CNVs less than 10 bp. For
QuantiSNP, we used the default settings, and then, following the
advice of the documentation, we omitted CNVs with a Log Bayes
Factor less than 30. For cnvPartition, we used the default settings,
except we varied the minimum number of consecutive probes
necessary to define a CNV (3, 5, or 10). For HMMSeg, for
homozygous deletion (loss) predictions, we required events to be at
least 3 probes and 1 kb in length with an average LRR value less
than 21. For hemizygous deletion events, we required at least 10
probes and 1 kb in length with an average LRR value ,20.25,
and we required the proportion of heterozygous SNP calls to be
less than 10%. For amplification events (gains), we required a
minimum of 10 probes and 1 kb in length, LRR values of greater
than 0.25, and BAF deviation values at heterozygous SNPs greater
than 0.05. For all results except those from HMMSeg, none of the
CNVs spanned the centromere (coordinates obtained from UCSC
genome browser database; http://genome.ucsc.edu). One CNV
identified by HMMSeg that spanned the centromere was split into
two separate CNVs on either side of the centromere region.
Besides these six different algorithms (PennCNV, QuantiSNP,
HMMSeg, and cnvPartition with a 3-, 5-, or 10-probe minimum),
we also looked at results where CNVs were required to be
identified by both the HMMSeg algorithm and the cnvPartition
algorithm (3-, 5-, or 10-probe minimum) for each subject/
chromosome combination. We also looked at results where CNVs
were required to be identified by HMMSeg, cnvPartition with a 3-
probe minimum, PennCNV, and QuantiSNP. In these instances,
the CNVs identified by the two or four algorithms had to overlap;
the start position of the resulting CNV was defined as the
minimum bp position of the two overlapping CNVs, and the end
position was defined as the maximum bp position of the
overlapping CNVs. We used two different methods to determine
whether two CNVs overlapped: (1) any overlap and (2) a condition
where the length of the overlap had to be at least 40% of the size of
at least one of the CNVs (denoted as the ‘‘40% either’’ criterion).
Figure 1 illustrates these two different methods. In all cases, losses
were compared only with losses, and gains were compared only
with gains.
Finding CNVs Previously Unreported in the Literature
To determine whether any of the CNVs we discovered in our
schizophrenia subjects had not yet been reported in the literature
and did not appear in our own normal control subjects, we first
compared all of our CNVs (from both our normal control and
schizophrenia subjects) to a database constructed from CNVs that
had been reported in the literature for normal subjects. We then
disregarded the CNVs we had discovered that were in this
‘‘normals’’ database and/or were present in our normal control
subjects. To determine whether we discovered any CNVs in our
schizophrenia subjects that had not been previously reported in
either normal or schizophrenia subjects and that were not present
in our own normal control subjects, we compared the remaining
CNVs in our schizophrenia subjects to a database constructed
from CNVs that had been reported in the literature for
schizophrenia subjects.
Constructing the Database of CNVs in Normal Subjects
from the Literature. To construct the database of CNVs that
have been reported in the literature for normal subjects, we
initially combined CNVs from six sources: Itsara et al. [19],
Database of Genomic Variants (DGV; http://projects.tcag.ca/
variation/)[18], ISC [20], Stefansson et al. [21], Walsh et al. [22],
and Xu et al. [23]. CNVs reported on X and Y chromosomes were
omitted. CNVs reported in Itsara et al. [19] and ISC [20] were
translated from hg17 to hg18 using LiftOver (http://genome.ucsc.
edu/cgi-bin/hgLiftOver). CNVs reported by Itsara et al. [19]
from the hgdp study were omitted because subjects had
neurological conditions. CNVs reported in Database of Genomic
Variants (DGV; http://projects.tcag.ca/variation/) that were less
than 10 bp were omitted, as were CNVs for which both gain and
loss were reported as blank or 0.
We denoted this database ‘‘CNVs in Normals from Lit’’ (see
Figure 2). This database contained CNVs that were reported as
gains and losses, as well as some CNVs that were reported as both
gains and losses (denoted ‘‘both’’). We then merged overlapping
CNVs to create a set of unique CNVs, and we denoted this
database ‘‘Merged CNVs in Normals.’’ When determining
whether CNVs overlapped, we compared gains only to gains or
both, and we compared losses only to losses or both. We used our
two different definitions of overlap (‘‘any’’ and ‘‘40% either’’) to
produce two distinct databases.
Constructing the Database of CNVs Not Previously
Discovered in Normal Subjects. To construct a database of
CNVs that we had discovered that were not previously reported in
normal subjects, we compared our CNVs with the ‘‘Merged CNVs
in Normals’’ database and kept only CNVs that did not overlap.
Again, we compared gains only to gains or both, and we compared
losses only to losses or both. We denoted this database ‘‘CNVs Not
Previously Discovered in Normals’’ (see Figure 2). We used our
two different definitions of overlap to produce two distinct
databases. From these remaining CNVs, we constructed a new
database by keeping only those CNVs that were present in our
schizophrenia subjects and not present in our normal control
subjects; we denoted this database ‘‘CNVs Found Only in SCZ,
Not Previously Discovered in Normals.’’
Constructing the Database of CNVs in Schizophrenia
Subjects from the Literature. To construct the database of
CNVs that had been reported in the literature for schizophrenia
subjects, we initially combined CNVs from four sources [20,22].
We denoted this database ‘‘CNVs in SCZ from Lit’’ (see Figure 2).
We then compared these CNVs with the CNVs in the ‘‘Merged
CNVs in Normals’’ database and kept only CNVs that did not
overlap. Again, we compared gains only to gains or both, and we
compared losses only to losses or both. We denoted this database
‘‘CNVs in SCZ from Lit, Not Previously Discovered in Normals.’’
We used our two different definitions of overlap to produce two
distinct databases.
Constructing the Database of CNVs Found Only in
Schizophrenia Subjects and Not Previously Reported in
Either Normal or Schizophrenia Subjects. To determine
whether we had discovered any CNVs in our schizophrenia
subjects that had not been previously reported in either normal or
schizophrenia subjects, we compared the CNVs in the database
‘‘CNVs Found Only in SCZ, Not Previously Discovered in
Normals’’ to the CNVs in the merged version of the database
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Again, we compared gains only to gains or both, and we compared
losses only to losses or both. We denoted this database ‘‘CNVs
Found Only in SCZ, Not Previously Discovered in Normals or
SCZ.’’ We used our two different definitions of overlap to produce
two distinct databases.
Statistical Analysis
All data manipulation and statistical computations using the
results of the CNV analyses were done in R version 2.8.1 [33].
Supporting Information
Figure S1 Mean, Min, Max, and Range of CNV sizes within
merged CNV Groups vs. number of CNVs in the group, using the
‘‘any’’ overlap criterion, for CNVs reported in the literature for
normal subjects.
Found at: doi:10.1371/journal.pone.0014456.s001 (2.80 MB TIF)
Figure S2 Mean, Min, Max, and Range of CNV sizes within
merged CNV groups vs. number of CNVs in the group, using the
‘‘40% either’’ overlap criterion, for CNVs reported in the
literature for normal subjects.
Found at: doi:10.1371/journal.pone.0014456.s002 (2.80 MB TIF)
Figure S3 Number of CNVs per chromosome for CNVs
reported in the literature for normal subjects, as well as number
of CNVs based on merging overlapping CNVs.
Found at: doi:10.1371/journal.pone.0014456.s003 (2.80 MB TIF)
Figure S4 Distribution of CNV size for CNVs reported in the
literature for normal subjects, as well as distribution of CNV size
based on merging overlapping CNVs.
Found at: doi:10.1371/journal.pone.0014456.s004 (2.80 MB TIF)
Figure S5 Range of sizes of overlapping CNVs (within
individual and chromosome) vs. chromosome for CNVs identified
by requiring HMMSeg, cnvPartition with a 3-probe minimum,
PennCNV, and QuantiSNP to all identify the CNV. N=102
CNV groups (15 gains; 87 losses).
Found at: doi:10.1371/journal.pone.0014456.s005 (2.80 MB TIF)
Figure S6 Process Flow Chart based on HMMSeg alone.
Found at: doi:10.1371/journal.pone.0014456.s006 (2.80 MB TIF)
Figure S7 Process Flow Chart based on cnvPartition (3-probe
minimum) alone.
Found at: doi:10.1371/journal.pone.0014456.s007 (2.80 MB TIF)
Figure S8 Process Flow Chart based on PennCNV alone.
Found at: doi:10.1371/journal.pone.0014456.s008 (2.80 MB TIF)
Figure S9 Process Flow Chart based on QuantiSNP alone.
Found at: doi:10.1371/journal.pone.0014456.s009 (2.80 MB TIF)
Figure S10 Process Flow Chart based on overlap between
HMMSeg, cnvPartition (3-probe minimum), PennCNV, and
QuantiSNP.
Found at: doi:10.1371/journal.pone.0014456.s010 (2.80 MB TIF)
File S1 Datasets S1–S10. Coordinates of CNVs not previously
published in databases of normal subjects.
Found at: doi:10.1371/journal.pone.0014456.s011 (0.24 MB
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